INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 430m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
Corporate insider
GS

Gray Susannah

DirectorCIK 0001833453

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 0
Max Insider Score9
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
13.4K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Theravance Biopharma, Inc.Director · Sep 24, 2026
  • Insider ofevidence
    ANAPTYSBIO, INCDirector · Apr 29, 2026
9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D
—
6,009 sh
Sep 23, 2026
Sep 24, 2026
traded Sep 23, 2026
+1d
SEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
42.1K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
32.7K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
22.0K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
23.6K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
TBPHTheravance Biopharma, Inc.
Disposition to issuer
D—
24.3K sh
Sep 23, 2026Sep 24, 2026
traded Sep 23, 2026
+1dSEC FORM 4

Evidence

9
GS
Gray SusannahDirector
ANABANAPTYSBIO, INC
Grant or award
A—
11.3K sh
Apr 27, 2026Apr 29, 2026
traded Apr 27, 2026
+2dSEC FORM 4

Evidence